Category: <span>Fundamental Analysis</span>

Chemometec

In this fundamental analysis report, analysts William Wastenson and Neo Fuchs take a closer look at ChemoMetec, a Danish medtech company supplying cell counting instruments to pharmaceutical
and biotech companies. The share price has declined approximately 50% following a temporary US government shutdown and two subsequent guidance reductions, yet the recurring revenue base continued growing throughout.

Puuilo

In this fundamental analysis report, analysts Theodor Hedvall and Olle Fransson take a closer look at Puuilo, a Finnish discount retailer focused on DIY products, consumables and household goods. Despite structurally stronger profitability than Nordic retail peers, the Company trades at 13.9x EV/EBIT on 2028E estimates, below its historical average of 16.5x, which the analysts believe underestimates Puuilo’s long-term growth runway and margin potential.

Sintercast

In this fundamental analysis report, analysts Esther Wärnsby and Gal Teyar take a closer look at SinterCast, a Swedish industrial technology company and the world’s leading supplier of high-volume Compacted Graphite Iron (CGI) process control systems. An equally weighted DCF and peer valuation yields a SEK 132 target price, corresponding to 26.5% upside.

CTT Systems

In this fundamental analysis report, analysts Isak Andersson and Viktor Komarek take a closer look at CTT Systems, a Swedish aerospace technology company developing and supplying active humidity control systems for commercial aircraft. Despite strong underlying demand, the CTT share price has been heavily pressured by distributor inventory effects, foreign exchange headwinds, institutional outflows, and broader concerns surrounding the aerospace industry.

I-tech

In this fundamental analysis report, analysts William Sjögren and Jakob Lewrén take a closer look at I-tech. The market has punished the company over exaggerated regulatory risks whilst underlying fundamentals and outlook remain strong.
An equally weighted DCF and relative valuation, where a 2027E EV/EBIT of 12x is applied, corresponds to an upside of 37.7%.

Paxman

In this fundamental analysis, analysts Dennis Drevell Smith and Anna-Brita Hunter Nilsson examine Paxman AB, a UK based MedTech company operating a de facto monopoly in mechanical scalp cooling. An equally weighted DCF and relative valuation imply a potential upside of 58%, making Paxman a compelling buy opportunity.

Careium

In this fundamental analysis report, analysts Måns Rössberger and Emma Rosberg take a closer look at Careium AB, a Swedish provider of telecare solutions for seniors. Despite market concerns related to management changes and prior deficiencies in financial communication, Careium is positioned to benefit from a structurally growing market driven by aging demographics, with revenue projected to grow at a 4.0% CAGR through 2027.